KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $3.3 million.

  • Castle Biosciences' Net Cash Flow fell 6460.0% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 million, marking a year-over-year decrease of 35168.63%. This contributed to the annual value of $20.9 million for FY2024, which is 18656.41% up from last year.
  • Per Castle Biosciences' latest filing, its Net Cash Flow stood at $3.3 million for Q3 2025, which was down 6460.0% from -$7.5 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Net Cash Flow registered a high of $24.8 million during Q4 2024, and its lowest value of -$139.0 million during Q3 2022.
  • For the 5-year period, Castle Biosciences' Net Cash Flow averaged around -$17.1 million, with its median value being -$8.1 million (2023).
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 259248.35% in 2022, then soared by 30182.76% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Net Cash Flow stood at -$33.5 million in 2021, then surged by 66.52% to -$11.2 million in 2022, then soared by 167.82% to $7.6 million in 2023, then surged by 224.89% to $24.8 million in 2024, then tumbled by 86.57% to $3.3 million in 2025.
  • Its Net Cash Flow stands at $3.3 million for Q3 2025, versus -$7.5 million for Q2 2025 and -$30.0 million for Q1 2025.